The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study

Paul J. Roach, Roslyn Francis, Louise Emmett, Edward Hsiao, Andrew Kneebone, George Hruby, Thomas Eade, Quoc A. Nguyen, Benjamin D. Thompson, Thomas Cusick, Michael McCarthy, Colin I. Tang, Bao Ho, Philip D. Stricker, Andrew M. Scott

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate followup questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion: 68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.

Original languageEnglish
Pages (from-to)82-88
Number of pages7
JournalJournal of Nuclear Medicine
Volume59
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Multicenter Studies
Prostatic Neoplasms
Prospective Studies
Recurrence
Diagnostic Imaging
Prostate
Lymph Nodes
Demography
Radiation

Cite this

Roach, Paul J. ; Francis, Roslyn ; Emmett, Louise ; Hsiao, Edward ; Kneebone, Andrew ; Hruby, George ; Eade, Thomas ; Nguyen, Quoc A. ; Thompson, Benjamin D. ; Cusick, Thomas ; McCarthy, Michael ; Tang, Colin I. ; Ho, Bao ; Stricker, Philip D. ; Scott, Andrew M. / The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer : Results of an australian prospective multicenter study. In: Journal of Nuclear Medicine. 2018 ; Vol. 59, No. 1. pp. 82-88.
@article{fd75bcf2689248f492718ca45917a836,
title = "The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study",
abstract = "68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate followup questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25{\%} of patients and for restaging/biochemical recurrence in 75{\%} of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51{\%} of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62{\%} change in management intent) than in patients undergoing primary staging (21{\%} change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27{\%} of patients, locoregional lymph nodes in 39{\%}, and distant metastatic disease in 16{\%}. Conclusion: 68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.",
keywords = "Management impact, PET/CT, Prostate cancer, PSMA",
author = "Roach, {Paul J.} and Roslyn Francis and Louise Emmett and Edward Hsiao and Andrew Kneebone and George Hruby and Thomas Eade and Nguyen, {Quoc A.} and Thompson, {Benjamin D.} and Thomas Cusick and Michael McCarthy and Tang, {Colin I.} and Bao Ho and Stricker, {Philip D.} and Scott, {Andrew M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2967/jnumed.117.197160",
language = "English",
volume = "59",
pages = "82--88",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "SOC Nuclear Medicine Inc",
number = "1",

}

Roach, PJ, Francis, R, Emmett, L, Hsiao, E, Kneebone, A, Hruby, G, Eade, T, Nguyen, QA, Thompson, BD, Cusick, T, McCarthy, M, Tang, CI, Ho, B, Stricker, PD & Scott, AM 2018, 'The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study' Journal of Nuclear Medicine, vol. 59, no. 1, pp. 82-88. https://doi.org/10.2967/jnumed.117.197160

The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer : Results of an australian prospective multicenter study. / Roach, Paul J.; Francis, Roslyn; Emmett, Louise; Hsiao, Edward; Kneebone, Andrew; Hruby, George; Eade, Thomas; Nguyen, Quoc A.; Thompson, Benjamin D.; Cusick, Thomas; McCarthy, Michael; Tang, Colin I.; Ho, Bao; Stricker, Philip D.; Scott, Andrew M.

In: Journal of Nuclear Medicine, Vol. 59, No. 1, 01.01.2018, p. 82-88.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer

T2 - Results of an australian prospective multicenter study

AU - Roach, Paul J.

AU - Francis, Roslyn

AU - Emmett, Louise

AU - Hsiao, Edward

AU - Kneebone, Andrew

AU - Hruby, George

AU - Eade, Thomas

AU - Nguyen, Quoc A.

AU - Thompson, Benjamin D.

AU - Cusick, Thomas

AU - McCarthy, Michael

AU - Tang, Colin I.

AU - Ho, Bao

AU - Stricker, Philip D.

AU - Scott, Andrew M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - 68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate followup questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion: 68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.

AB - 68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate followup questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion: 68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.

KW - Management impact

KW - PET/CT

KW - Prostate cancer

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85040046196&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.197160

DO - 10.2967/jnumed.117.197160

M3 - Article

VL - 59

SP - 82

EP - 88

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -